ID: ALA553565

Max Phase: Preclinical

Molecular Formula: C14H23ClN5O4P

Molecular Weight: 391.80

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)OP(=O)(COCCn1cnc2c(Cl)nc(N)nc21)OC(C)C

Standard InChI:  InChI=1S/C14H23ClN5O4P/c1-9(2)23-25(21,24-10(3)4)8-22-6-5-20-7-17-11-12(15)18-14(16)19-13(11)20/h7,9-10H,5-6,8H2,1-4H3,(H2,16,18,19)

Standard InChI Key:  VPODKOINXYQOJB-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 391.80

Molecular Weight (Monoisotopic): 391.1176

AlogP: 3.08

#Rotatable Bonds: 9

Polar Surface Area: 114.38

Molecular Species: NEUTRAL

HBA: 9

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 2.05

CX LogP: 1.98

CX LogD: 1.98

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.39

Np Likeness Score: -0.96

References

1. Holý A, Günter J, Dvoráková H, Masojídková M, Andrei G, Snoeck R, Balzarini J, De Clercq E..  (1999)  Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.,  42  (12): [PMID:10377214] [10.1021/jm9811256]

Source

Source(1):

• Scientific Literature